Phase 2 study of AU-011 for primary choroidal melanoma underway

The first patient has been dosed in a phase 2 clinical trial investigating safety and efficacy of suprachoroidal administration of AU-011 as a potential treatment for primary choroidal melanoma, according to a press release.
Aura Biosciences is the licensing partner of Clearside Biomedical for the development of AU-011 for the treatment of primary choroidal melanoma. Aura is using Clearside’s SCS microinjector to deliver the treatment, the release said.
AU-011 passed the safety review for the first dose escalation cohort, which noted no adverse events.
“With this trial initiation, we

Full Story →